Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Short term Debt (2016 - 2025)

Historic Short term Debt for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $1.6 million.

  • Immucell's Short term Debt rose 762.5% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 762.5%. This contributed to the annual value of $1.5 million for FY2024, which is 481.6% up from last year.
  • As of Q3 2025, Immucell's Short term Debt stood at $1.6 million, which was up 762.5% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Immucell's Short term Debt ranged from a high of $1.6 million in Q3 2025 and a low of $767517.0 during Q1 2021
  • Over the past 5 years, Immucell's median Short term Debt value was $1.1 million (recorded in 2023), while the average stood at $1.2 million.
  • Per our database at Business Quant, Immucell's Short term Debt crashed by 2583.6% in 2021 and then skyrocketed by 4138.26% in 2023.
  • Over the past 5 years, Immucell's Short term Debt (Quarter) stood at $812207.0 in 2021, then grew by 27.98% to $1.0 million in 2022, then surged by 37.46% to $1.4 million in 2023, then rose by 4.82% to $1.5 million in 2024, then increased by 6.29% to $1.6 million in 2025.
  • Its Short term Debt stands at $1.6 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.5 million for Q1 2025.